This includes an overexpression of tenascin-C at the invasive front [590], increasing motility of glioma cells via interactions with β1 or αvβ3 integrins [591], probably via an activation of FAK and inhibition of RhoA [592,593,594]. The gene discussed is PTK2; the disease is central nervous system cancer.